Terms: = Pancreatic cancer AND POU5F1, MGC22487, 5460, ENSG00000230336, POU5F1P1, OTF3P1, Oct4, OCT4, OCT3, OTF3C, OTF4, OTF3 AND Prognosis
18 results:
1. Octamer-binding transcription factor 4-positive circulating tumor cell predicts worse treatment response and survival in advanced cholangiocarcinoma patients who receive immune checkpoint inhibitors treatment.
Pei F; Tao Z; Lu Q; Fang T; Peng S
World J Surg Oncol; 2024 Apr; 22(1):110. PubMed ID: 38664770
[TBL] [Abstract] [Full Text] [Related]
2. Biomimetic Microenvironmental Stiffness Boosts Stemness of pancreatic Ductal Adenocarcinoma via Augmented Autophagy.
Gong T; Wu D; Pan H; Sun Z; Yao X; Wang D; Huang Y; Li X; Guo Y; Lu Y
ACS Biomater Sci Eng; 2023 Sep; 9(9):5347-5360. PubMed ID: 37561610
[TBL] [Abstract] [Full Text] [Related]
3. Blood exosome marker miRNA-30d-5p: Role and regulation mechanism in cell stemness and gemcitabine resistance of hepatocellular carcinoma.
Tang B; Xie L; Tang X; Tian J; Xiao S
Mol Cell Probes; 2023 Oct; 71():101924. PubMed ID: 37536457
[TBL] [Abstract] [Full Text] [Related]
4. Blood-based Proteomic Signatures Associated With MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression.
Fahrmann JF; Wasylishen AR; Pieterman CRC; Irajizad E; Vykoukal J; Wu R; Dennison JB; Peterson CB; Zhao H; Do KA; Halperin DM; Agarwal SK; Blau JE; Jha S; Rivero JD; Nilubol N; Walter MF; Welch JM; Weinstein LS; Vriens MR; van Leeuwaarde RS; van Treijen MJC; Valk GD; Perrier ND; Hanash SM; Katayama H
J Clin Endocrinol Metab; 2023 Nov; 108(12):3260-3271. PubMed ID: 37307230
[TBL] [Abstract] [Full Text] [Related]
5. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.
Zhou T; Xie Y; Hou X; Bai W; Li X; Liu Z; Man Q; Sun J; Fu D; Yan J; Zhang Z; Wang Y; Wang H; Jiang W; Gao S; Zhao T; Chang A; Wang X; Sun H; Zhang X; Yang S; Huang C; Hao J; Liu J
J Exp Clin Cancer Res; 2023 May; 42(1):111. PubMed ID: 37143164
[TBL] [Abstract] [Full Text] [Related]
6. A non-metabolic function of hexokinase 2 in small cell lung cancer: promotes cancer cell stemness by increasing USP11-mediated CD133 stability.
Wang J; Shao F; Yang Y; Wang W; Yang X; Li R; Cheng H; Sun S; Feng X; Gao Y; He J; Lu Z
Cancer Commun (Lond); 2022 Oct; 42(10):1008-1027. PubMed ID: 35975322
[TBL] [Abstract] [Full Text] [Related]
7. MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas.
Luan Z; Morimoto Y; Fushimi A; Yamashita N; Suo W; Bhattacharya A; Hagiwara M; Jin C; Kufe D
Carcinogenesis; 2022 Feb; 43(1):67-76. PubMed ID: 34657147
[TBL] [Abstract] [Full Text] [Related]
8. LRH-1 (liver receptor homolog-1) derived affinity peptide ligand to inhibit interactions between β-catenin and LRH-1 in pancreatic cancer cells: from computational design to experimental validation.
Pouraghajan K; Mahdiuni H; Ghobadi S; Khodarahmi R
J Biomol Struct Dyn; 2022 Apr; 40(7):3082-3097. PubMed ID: 33183172
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic value of octamer binding transcription factor 4 for patients with solid tumors: A meta-analysis.
Zhao X; Lu H; Sun Y; Liu L; Wang H
Medicine (Baltimore); 2020 Oct; 99(42):e22804. PubMed ID: 33080755
[TBL] [Abstract] [Full Text] [Related]
10. Markers of pancreatic cancer stem cells and their clinical and therapeutic implications.
Gzil A; Zarębska I; Bursiewicz W; Antosik P; Grzanka D; Szylberg Ł
Mol Biol Rep; 2019 Dec; 46(6):6629-6645. PubMed ID: 31486978
[TBL] [Abstract] [Full Text] [Related]
11. TSPAN8 promotes cancer cell stemness via activation of sonic Hedgehog signaling.
Zhu R; Gires O; Zhu L; Liu J; Li J; Yang H; Ju G; Huang J; Ge W; Chen Y; Lu Z; Wang H
Nat Commun; 2019 Jun; 10(1):2863. PubMed ID: 31253779
[TBL] [Abstract] [Full Text] [Related]
12. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract] [Full Text] [Related]
13. Notch pathway inhibition targets chemoresistant insulinoma cancer stem cells.
Capodanno Y; Buishand FO; Pang LY; Kirpensteijn J; Mol JA; Argyle DJ
Endocr Relat Cancer; 2018 Feb; 25(2):131-144. PubMed ID: 29175872
[TBL] [Abstract] [Full Text] [Related]
14. Leptin-Notch signaling axis is involved in pancreatic cancer progression.
Harbuzariu A; Rampoldi A; Daley-Brown DS; Candelaria P; Harmon TL; Lipsey CC; Beech DJ; Quarshie A; Ilies GO; Gonzalez-Perez RR
Oncotarget; 2017 Jan; 8(5):7740-7752. PubMed ID: 27999190
[TBL] [Abstract] [Full Text] [Related]
15. Roles of oct4 in tumorigenesis, cancer therapy resistance and prognosis.
Villodre ES; Kipper FC; Pereira MB; Lenz G
Cancer Treat Rev; 2016 Dec; 51():1-9. PubMed ID: 27788386
[TBL] [Abstract] [Full Text] [Related]
16. COUP-TFII in pancreatic adenocarcinoma: clinical implication for patient survival and tumor progression.
Polvani S; Tarocchi M; Tempesti S; Mello T; Ceni E; Buccoliero F; D'Amico M; Boddi V; Farsi M; Nesi S; Nesi G; Milani S; Galli A
Int J Cancer; 2014 Apr; 134(7):1648-58. PubMed ID: 24122412
[TBL] [Abstract] [Full Text] [Related]
17. Knockdown of oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells.
Lu Y; Zhu H; Shan H; Lu J; Chang X; Li X; Lu J; Fan X; Zhu S; Wang Y; Guo Q; Wang L; Huang Y; Zhu M; Wang Z
Cancer Lett; 2013 Oct; 340(1):113-23. PubMed ID: 23872274
[TBL] [Abstract] [Full Text] [Related]
18. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment.
Bao B; Ali S; Ahmad A; Azmi AS; Li Y; Banerjee S; Kong D; Sethi S; Aboukameel A; Padhye SB; Sarkar FH
PLoS One; 2012; 7(12):e50165. PubMed ID: 23272057
[TBL] [Abstract] [Full Text] [Related]
